In 2005, California Stem Cell Inc. was founded to address what I
perceived to be a critical gap in the path from initial drug discovery
to publicly available, clinically proven treatments. Although stem cells
were beginning to show great potential in their ability to address
human injury and illness, few companies existed with the means and
ability to bridge that gap, and were capable of taking on the financial
and regulatory challenges present in translating novel academic
discoveries into viable cell therapies for patients in need. With that
in mind, I set out with a group of highly talented colleagues to create a
company capable of doing just that.
With remarkable efficiency,
California Stem Cell has created a pipeline of advanced clinical
programs testing promising stem cell-based therapies, underpinned by
truly outstanding manufacturing and regulatory capabilities.
Now,
in 2014, I am happy to announce a change to our organization that we
firmly believe will help us better realize our vision. NeoStem, Inc., a
leader in the emerging cellular therapy industry, has acquired
California Stem Cell in a manner that is mutually beneficial for
ourselves, NeoStem, and most importantly, the patients we care so much
about. This acquisition will enable us to fund the expansion and
advancement of our clinical pipeline of therapies, with additional
talent and resources, so we may reach a greater number of patients in a
shorter period of time.
The entire team at California Stem Cell is
deeply appreciative of the support we have received, proud to announce
this major advancement, and committed to the continued growth of our
cell therapy pipeline on behalf of patients everywhere.
Sincerely,
Hans S. Keirstead
California
Stem Cell (CSC) is focused on the application of high-purity human
cells in developing life changing therapies, including a platform cancer
technology which has been approved to enter Phase III clinical trials,
with Special Protocol Assessment (SPA) and Fast Track designation, in
metastatic melanoma.
Since its founding in 2005, CSC has developed
proprietary methods for the scalable production of high-purity human
stem cells and their derivates. The ability to generate these cell types
at high-purity in large quantities has put CSC in the unique position
to address critical unmet needs in the development of life-changing
therapies. CSC is currently conducting clinical trials investigating its
patient specific cancer immunotherapy, a platform technology in
development as a treatment for a broad range of cancers.
No comments:
Post a Comment